東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Dyslipidemias = pathophysiology, eva...

Garg, Abhimanyu.

Linked to FindBook

Google Book

Amazon

博客來

Dyslipidemias = pathophysiology, evaluation and management /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Dyslipidemias/ edited by Abhimanyu Garg.
Reminder of title:	pathophysiology, evaluation and management /
other author:	Garg, Abhimanyu.
Published:	Totowa, NJ :Humana Press : : 2015.,
Description:	xvi, 525 p. :ill., digital ;24 cm.
[NT 15003449]:	Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
Contained By:	Springer eBooks
Subject:	Lipids - Metabolism -
Online resource:	http://dx.doi.org/10.1007/978-1-60761-424-1
ISBN:	9781607614241 (electronic bk.)

Dyslipidemias = pathophysiology, evaluation and management /
Dyslipidemiaspathophysiology, evaluation and management /[electronic resource] :edited by Abhimanyu Garg. - Totowa, NJ :Humana Press :2015. - xvi, 525 p. :ill., digital ;24 cm. - Contemporary endocrinology. - Contemporary endocrinology..

Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.

Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.

ISBN: 9781607614241 (electronic bk.)

Standard No.: 10.1007/978-1-60761-424-1doiSubjects--Topical Terms:

2153541
Lipids
--Metabolism

LC Class. No.: RC632.L5

Dewey Class. No.: 616.3997

Dyslipidemias = pathophysiology, evaluation and management /
LDR:03961nmm a2200325 a 4500 001 2006549
003 DE-He213
005 20160107150140.0
006 m d
007 cr nn 008maaau
008 160114s2015 nju s 0 eng d
020 $a 9781607614241 (electronic bk.)
020 $a 9781607614234 (paper)
024 7 $a 10.1007/978-1-60761-424-1 $2 doi
035 $a 978-1-60761-424-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC632.L5
072 7 $a MJG $2 bicssc
072 7 $a MED027000 $2 bisacsh
082 0 4 $a 616.3997 $2 23
090 $a RC632.L5 $b D998 2015
245 0 0 $a Dyslipidemias $h [electronic resource] : $b pathophysiology, evaluation and management / $c edited by Abhimanyu Garg.
260 $a Totowa, NJ : $b Humana Press : $b Imprint: Humana Press, $c 2015.
300 $a xvi, 525 p. : $b ill., digital ; $c 24 cm.
490 1 $a Contemporary endocrinology
505 0 $a Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
520 $a Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
650 0 $a Lipids $x Metabolism $x Disorders $x Pathophysiology. $3 2153541
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Endocrinology. $3 610914
650 2 4 $a Internal Medicine. $3 858559
650 2 4 $a Primary Care Medicine. $3 894341
650 2 4 $a Cardiology. $3 861477
650 2 4 $a Pediatrics. $3 559143
700 1 $a Garg, Abhimanyu. $3 2153540
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Contemporary endocrinology. $3 1566840
856 4 0 $u http://dx.doi.org/10.1007/978-1-60761-424-1
950 $a Medicine (Springer-11650)